Fred Ehrenkranz Cohen
Founder of 6 different companies, including: Kyverna Therapeutics, Inc., Monograph Capital Partners I LP and TPG Biotechnology Partners LP, Fred Ehrenkranz Cohen and presently occupies the position of Senior Managing Director at VV Manager LLC (which he founded in 2017) and Chairman of Monograph Capital Partners I LP (which he founded in 2021). Dr. Cohen is also Member of American Academy of Arts & Sciences, Member of National Academy of Medicine (United States), Member of Association of American Physicians, Member of American Society for Clinical Investigation, Member of National Academy of Medicine and Managing Director & Partner at Tarrant Capital IP LLC and on the board of 14 other companies.
In his past career he was Director at Rapid Micro Biosystems, Inc., Chairman for Cell Design Labs, Inc. (he founded the company in 2016), Senior Director-Business Development at Kosan Biosciences, Inc., Managing Director at The Plastics Group, Inc., Managing Director & Partner at TPG Biotechnology Partners LP (he founded the company in 2001), Senior Managing Partner at Vida Ventures LLC (he founded the company in 2017), Advisor at CHV Capital, Inc., Partner at TPG Capital LLC and Professor at The University of California, San Francisco.
He received an undergraduate degree from Yale University, a doctorate from the University of Oxford and a doctorate from Stanford University.
|06/14/2022||5,197||Award at $0 per share.||0|
|06/23/2021||2,094||Award at $0 per share.||0|
|01/20/2021||20,000||Derivative/Non-derivative trans. at $13.78 per share.||275,600|
|03/01/2019||10,000||Award at $16.89 per share.||168,900|